Fewer Women with Breast Cancer Will Be Getting Chemotherapy

Ebony Scott
June 6, 2018

Her breast cancer had come back with a vengeance after a 2003 mastectomy and she had big tumors in her chest and on her liver.

"The study is going to provide women a piece of information to help them make a very hard decision", said the survivor now celebrating 10-years being cancer-free.

"The impact is tremendous", said the study leader, Dr. Joseph Sparano of Montefiore Medical Center in NY.

Now cancer scientists across the globe are looking at how this new research - which was published in Nature Medicine today - can be applied to any type of cancer. "I spoke to four people about her case, including one of the doctors associated with the Tailorx trial", said Dr Ramesh Sarin, senior consultant surgical oncology at the Indraprastha Apollo Hospitals. They benefit just as much from chemotherapy, which many don't tolerate well and can have long-term consequences, as they do from hormone treatments, which have many fewer side effects.

'These findings, showing no benefit from receiving chemotherapy plus hormone therapy for most patients in this intermediate-risk group, will go a long way to support oncologists and patients in decisions about the best course of treatment, ' Dr. Jeffrey Abrams, associate director of the National Cancer Institute's Cancer Therapy Evaluation Program, said in a statement.

"Part of the excitement is because all cancers contain mutations, it's a technique that could potentially be applied to any tumor type", Rosenberg said. Women with an RS of 10 or lower (1619, 17%) were in the ET arm and those with a RS of 26 or higher (1389, 14%) were in the CET arm.

Cancer doctors said the findings would change practice in United Kingdom clinics, and meant women in this group could be treated safely with just surgery and hormone therapy.

Texting also played a role in helping patients feel like they were in control of their treatment, particularly during the first month.

What will she tell women who under prior guidelines received chemo and all its side effects and didn't need it after all?

Oliver Luck to be commissioner and CEO of XFL
He said that the XFL will allow him to reimagine how football is played on the field and delivered to fans. This is not Luck's first experience with an upstart football league.

Qualcomm launches Snapdragon 850 platform, boosts "Always Connected" Windows 10 PCs
Notebooks and hybrid devices based on the Windows 10 operating system will be released before the holiday season this year. Aqstic support can be supported on both USB Type-C and 3.5mm jack.

Apple wants you to spend less time on your iPhone
You can now set an ending time for do not disturb - for 1 hour, until a certain period, or when you leave a location or meeting. But it's still all there - it's a bit like throwing your papers into a pile, rather than getting rid of things you don't need.

Immunotherapy trains a patient's own immune cells to recognise and fight cancer.

However, the results of the TAILORx trial show only 30 per cent of women with this particular form of early-stage breast cancer benefit from the treatment.

The study is thought to be the largest breast cancer treatment trial ever conducted. Oncotype DX costs around $4,000, which Medicare and many insurers cover. About 84 percent also had no signs of cancer, so chemo treatment had no impact.

For many breast cancer patients, one of the most hard treatment decisions is whether or not to go through chemotherapy.

The global trial, known as TAILORx, involved over 10,000 women from 1,182 research units in Ireland, the US, Canada, Australia, New Zealand and Peru.

A patient's tumour is genetically analysed to identify the rare changes that might make the cancer visible to the immune system.

Researchers share preliminary and more advanced results. Key secondary end points included freedom from recurrence of breast cancer at a distant site, freedom from recurrence of breast cancer at a distant or local-regional site, and overall survival (OS).

Perkins underwent several rounds of chemotherapy but the cancer kept spreading and doctors gave her just months to live.

"Irish women contributed significantly to this trial and can be rightly proud of their input into improving care for future women who present with breast cancer".

Other reports by GizPress

Discuss This Article

FOLLOW OUR NEWSPAPER